Cardioprotective effects of exercise training on doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis of preclinical studies

Figures

• 

  Figure 1. Flow chart of the study selection procedure.

• 

  Figure 2. Study quality graph based on Cochrane Collaboration criteria.

• 

  Figure 3. Overall effects of exercise training in fractional shortening of cardiac function of experimental models of doxorubicin-induced cardiomyopathy. Hydock et al., 2008 treadmill group (a) at day 5 and (b) at day 10, (c) wheel running group at day 5 and (d) at day 10; Hydock et al., 2011 (a) treadmill group, (b) wheel running group; Hydock et al., 2012 (a) 15 mg/kg and (b) 20 mg/kg cumulative dose of DOX; Jensen et al., 2013 treadmill group (a) at day 1, (b) at day 3, (c) at day 5, (d) at day 7 and (e) at day 9, wheel running group (f) at day 1, (g) at day 3, (h) at day 5, (i) at day 7 and (j) at day 9; Lien et al., 2015 treadmill group receiving (a) 10 mg/kg and (b) 15 mg/kg cumulative dose of DOX, wheel running group receiving (c) 10 mg/kg and (d) 15 mg/kg cumulative dose of DOX; Parry et al., 2015 wheel running group (a) at day 1, (b) at day 3 and (c) at day 5; Wang et al., 2018 mice (a) C57BL/6 and (b) Athymic Swiss Nude.

• 

  Figure 4. Effects of the timing of exercise protocol in relation to doxorubicin exposure (before vs. concomitantly and/or after) on fractional shortening of animals with doxorubicin-induced cardiomyopathy.

• 

  Figure 5. Sensitivity analysis of changes in fractional shortening (FS) based on clinical predictors of exercise training success. Unpaired Student’s T test, p < 0.05.